McKesson Corporation has released its first Advancing Community Oncology Report, providing an in-depth analysis of trends affecting community-based oncology practices across the United States and exploring opportunities for physicians to shape the future of patient care. The report draws on findings from a double-blind national survey of over 100 community oncologists and more than 100 practice administrators and staff, complemented by insights from McKesson’s inaugural Accelerate conference, which brought together over 1,500 physicians, clinicians, practice leaders, and industry experts to discuss the evolution of community oncology.
Health Technology Insights: Ryder and BJC Win Award for Healthcare Supply Chain Innovation
Jason Hammonds, president of Oncology & Multispecialty at McKesson, highlighted that more than half of cancer patients in the U.S. now receive care in community settings, creating both challenges and opportunities for providers and biopharma companies. Hammonds emphasized that McKesson’s Oncology services aim to bridge the gap between scientific innovation and everyday oncology practice. He noted that the report provides a platform for community practices to share their perspectives on patient care and for biopharma companies to better support these providers in advancing cancer treatment.
Health Technology Insights: Merck Reports Positive Phase 3 Results for DOR/ISL HIV Therapy
The report identifies several key areas where collaboration between community oncology practices and biopharma can improve patient outcomes. First, accelerating the adoption of novel and precision therapies is critical. Nearly 95 percent of surveyed oncologists expect personalized medicine to enhance patient survival, yet 78 percent indicate difficulty in keeping pace with new therapies, highlighting the need for additional practice support. Second, expanding access to community-based clinical trials remains a priority, as 93 percent of oncologists and administrators see clinical trials as beneficial for patients, but many report barriers to participation in their local settings. Third, adapting care to meet changing patient needs is essential. Rising patient volumes, long-term care requirements, and an increasing number of younger cancer patients demand tailored education and support resources.
The report also underscores the growing role of technology in community oncology. A majority of oncologists (84 percent) and administrators (87 percent) anticipate that artificial intelligence will become central to both clinical and administrative functions, though better integration into daily workflows is necessary to maximize impact. McKesson’s Accelerate conference showcased how precision medicine, AI, and improved access to clinical trials can empower community practices to provide high-quality, patient-centered care.
Michelle Lockyer, chief strategy officer for Oncology at McKesson, emphasized that as therapies become more targeted and clinical trials evolve, community practices are essential in translating innovation into patient access. Lockyer stated that McKesson’s unique position in the oncology ecosystem enables it to connect biopharma innovators, providers, payers, and technology partners, ensuring that scientific progress translates into meaningful real-world outcomes. She noted that the report highlights immediate opportunities for biopharma to enhance its support of community oncology practices while strengthening patient care and advancing treatment access.
Health Technology Insights: Medscape Launches AI-Powered Medical Intelligence for HCPs
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
